Brochure
7 Oct 2020

Dabired (Dabigatran Pellets)

PDF 1.7 MB

Dabired is ready to fill Dabigatran Etexilate Mesylate 42.04% w/w pellets which are designed to integrate seamlessly into your encapsulation process.

Content provided by our supplier

Dr. Reddy's Laboratories SA

  • CH
  • 2015
    On CPHI since
  • 3
    Certificates
  • 5000+
    Employees
Company types
Generics/Biosimilars Manufacturer
Primary activities
API Producer
Chemical Development
Generic APIs producer
Pharmaceutical Company (generic finished products)

Other Content from Dr. Reddy's Laboratories SA (9)

  • News Pharma Explained: Active Pharmaceutical Ingredients

    What are APIs? As the name suggests, Active Pharmaceutical Ingredients (APIs) are the heart of any dosage form, whether they are oral, injectable or inhaled, and are absolutely essential to the development of a formulated product.
  • Brochure Sugammadex Sodium API article

    Sugammadex sodium is one of the key molecules in Dr. Reddy’s API portfolio and an ideal use case on how a thorough understanding of the interaction between API and formulation can significantly improve the robustness of the formulation process considering the drug substance’s proneness to degradation in the formulation process, specifically during the terminal sterilization (TS) process for intravenous injection.
  • News Live Webinar: Strengthening a sustainable API supply chain performance.

    At Dr. Reddy’s, we’re in the business of ensuring good health for both people and the planet. Our experts will share insights on our sustainability approach and on how it helps B2B customers support their sustainable supply chain performance while sourcing APIs. Please register here: 
  • Brochure Dutasteride

    • We offer polymorphic crystalline form 2.• A novel synthetic process developed for crystalline form 2.• Quality by design (QBD) based API development for a consistent quality profile
  • News Dr. Reddy’s partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a potential treatment of COVID-19

    Dr. Reddy's Laboratories Ltd. announces partnering with FUJIFILM Corporation through FUJIFILM Toyama Chemical Co. Ltd.  and Global Response Aid for the development, manufacture and sales of Avigan® Tablets (generic name: favipiravir), a potential treatment of COVID-19.
  • Brochure Pregabalin API

    Crystalline form-I i.e., Innovator form.• The control strategy for the API impurity prole has been designed through quality-by-design (QbD) based development.• Lactam impurity levels are not detected, thus able to achieve USP/ EP compliance after milling - opening a possibility for a wide range of delivery systems
  • News Dr. Reddy's Laboratories launches Customer Service Portal to increase operational efficiency for API customers

    Dr. Reddy’s Laboratories Ltd. announces the launch of its advanced B2B Customer Service Portal “XCEED.”
  • Webinar Strengthening Diversity, Equity, and Inclusion in Pharma

    The pharma industry is aware that it needs to improve the representation of women and minority communities in its businesses. The benefits of diverse teams are clear, yet it isn’t an easy road. How can companies create an environment where people feel safe, thrive, and attract the best?
    Approaching Diversity and Inclusion as part of a wider Sustainability / Environment, Social, and Governance (ESG) performance is an essential indicator of pharma companies' commitment to driving I&D for a more diverse and successful workplace, which ultimately also ensures to better serve patients around the world.
  • Video Innovation Across Borders: How Pharma and innovators are fighting back against COVID-19 and ways forward

    A global pandemic demands a fast response. The research-based pharmaceutical industry is working upstream at extraordinary speed to develop a safe and effective vaccine for COVID19. Pharmaceutical companies around the globe are joining forces and speeding up the process by conducting phases and development in parallel and forging new partnerships and collaboration. The pharmaceutical and life science industry has faced the need to leverage science and technology, developed pre and during the pandemic. Firms are coming up with new ways to maintain production despite disrupted supply chains, or they are mobilizing to design new products as demand for existing products collapses. This discussion will examine how the COVID-19 pandemic is driving pharma and life science companies to collaborate, innovate and prepare for an uncertain future. This webinar was originally aired as part of the CPHI Festival of Pharma.